Mucke Hermann A M, Mucke Peter M
HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria.
IDrugs. 2010 Jan;13(1):30-7.
An analysis of patent applications that address strategies for the pharmacological treatment of retinal diseases that are not directly related to VEGF inhibition, published under the PCT during the 18-month period from January 2008 to June 2009, is presented. The largest number of therapeutic patent applications focused on attempts to correct visual cycle dysfunctions, complement overactivation or beta-amyloid deposition in drusen to control age-related macular degeneration (AMD). Biomarker-based and genetic diagnostic modalities that assess AMD risk were also frequently claimed in the patent applications, and have become a significant factor in patenting for ocular disorders. The fields of both visual cycle therapy and AMD biomarkers were dominated by non-corporate patent assignees. Diabetic retinopathy has not received as much attention from inventors compared with AMD; retinopathy of prematurity remains a field in which little specific patenting occurs.
本文对2008年1月至2009年6月这18个月期间根据《专利合作条约》（PCT）公布的、涉及与VEGF抑制无直接关系的视网膜疾病药物治疗策略的专利申请进行了分析。数量最多的治疗性专利申请集中在试图纠正视觉循环功能障碍、补充玻璃膜疣中的过度激活或β-淀粉样蛋白沉积以控制年龄相关性黄斑变性（AMD）。基于生物标志物和基因诊断的评估AMD风险的方法在专利申请中也经常被提及，并且已成为眼部疾病专利申请的一个重要因素。视觉循环治疗和AMD生物标志物这两个领域均由非企业专利受让人主导。与AMD相比，糖尿病性视网膜病变未受到发明者同样多的关注；早产儿视网膜病变仍然是一个专利申请较少的领域。
